Maintenance of remission with 6-week interval of tocilizumab in RA patients who have been in remission

Maintenance of remission with 6-week interval of tocilizumab in RA patients who have been in remission - Maintenance of remission by 6-week tocilizumab in RA patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015482

Enrollment

Registered

2014-10-21

Start date

2013-09-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: RA Patients who have been treated with tocilizumab for more than 6 months and have been in remisison for more than 3 months

Exclusion criteria

Exclusion criteria: Patients who have taken more than 5 mg/day of prednisolone

Design outcomes

Primary

Measure	Time frame
remission rate at 1 year after 6-week interval of tocilizumab therapy (DAS28-ESR &/or SDAI)	—

Countries

Japan

Contacts

Public ContactKoichi Amano

Saitama Medical Center, Saitama Medical University Saitama Medical Center, Saitama Medical Univers Department of Rheumatology and Clinical Immunology

amanokoi@saitama-med.ac.jp049-228-3859

Outcome results